Ophthotech isn’t taking a wait-and-see attitude towards eye disease. The biopharmaceutical company is developing a new treatment for wet age-related macular degeneration (wet AMD), the leading cause of blindness in the elderly. Ophthotech’s most promising candidate is Fovista, a drug to be used in conjunction with Genentech's Lucentis. Fovista, which is injected into the eye, has entered phase 3 clinical trials. Another candidate, Zimura, is being developed for the treatment of geographic atrophy, a form of dry AMD. The company went public in 2013.